A Cochrane review [withdrawn from publication] included 9 studies with a total of 434 subjects. There was no significant effect of SAMe on all-cause mortality (relative risks (RR) 0.62, 95% CI 0.30 to 1.26), liver-related mortality (RR 0.68, 95% CI 0.31 to 1.48), all-cause mortality or liver transplantation (RR 0.55; 95% CI 0.27 to 1.09), or complications (RR 1.35, 95% CI 0.84 to 2.16), but the analysis is based mostly on one trial only (n=123).
Comment: The quality of evidence is downgraded by imprecise results (few patients and wide confidence intervals) and by inconsistency (variability in results across studies).